Background: Septic shock represents the major cause of infection-associated mortality in the intensive care unit. The possibility that combination antibiotic therapy of bacterial septic shock improves outcome is controversial. Current guidelines do not recommend combination therapy except for the express purpose of broadening coverage when resistant pathogens are a concern.
S everal studies have shown that appropriate antimicrobial therapy, defined as the use of at least one agent with in vitro activity for the isolated pathogen, leads to lower mortality rates in life-threatening infections associated with sepsis (1) (2) (3) (4) (5) . The incremental benefit of combination as opposed to single-agent antimicrobial therapy in such situations is controversial (6 -10) .
Some clinical studies of bacterial infection, including endocarditis, Gramnegative bacteremia, and neutropenic sepsis (11) (12) (13) , and animal models of severe infection (14 -16) have supported the possibility of clinically relevant antimicrobial synergism with appropriate combinations of antibiotics. However, two separate meta-analyses have failed to demonstrate any consistent benefit with combination therapy in immunocompetent patients with sepsis and/or Gramnegative bacteremia (17, 18) .
The beneficial effect of early appropriate antimicrobial therapy appears to be most important in critically ill patients, particularly those with septic shock (5) . Given these data and in view of a recent meta-regression study that suggests that the beneficial effect of combination therapy may be restricted to patients with life-threatening infection at highest risk for death (19) , we performed a propensity-matched study examining the impact of early combination antibiotic therapy in adult patients with bacterial septic shock using a multinational septic shock database. The hypothesis of this study was that early combination antimicrobial therapy of septic shock as defined by the use of at least two antibiotics (of different mechanistic classes) with in vitro activity against the isolated pathogen is associated with reduced mortality.
SUBJECTS AND METHODS
A retrospective review of adult (age 18 yrs or older) patients with septic shock was performed. A waived consent protocol was approved by the Health Ethics Board of the University of Manitoba and at each individual participating center. Consecutive adult septic shock patients from 28 medical institutions in Canada, United States, and Saudi Arabia for periods between 1996 and 2007 were retrospectively identified using internal intensive care unit registries/databases and/or International Classification of Diseases (9 or 10) coding strategies. Each institution contributed a minimum of 50 cases. Each potential case was screened to determine whether the case met specific criteria for septic shock as described by the 1991 Society of Critical Care Medicine/ American College of Chest Physicians Consensus Statement on Sepsis Definitions (20) . The process used to identify the final study population is outlined in Figure 1 .
Data Elements and Definitions
Clinical infection definitions were adapted from previous recommendations or studies (21) (22) (23) . To qualify as potential pathogens causing shock, isolates from anatomical sites and/or blood cultures were required to have been obtained within 48 hrs of onset of shock.
A priori criteria were developed to uniformly determine the primary pathogen/ pathogens and to assess the appropriateness of antimicrobial therapy across participating institutions (Appendices 1 and 2). The first use of any appropriate antimicrobial therapy (i.e., with in vitro activity for the primary isolated pathogen or pathogens) was determined for all cases. For the purposes of this study, antibiotic monotherapy was defined as the administration of any single, appropriate, intravenous, preferably bactericidal (see Appendix 2 for exceptions) antibiotic at any point after the onset of recurrent or persistent hypotension. Combination therapy was defined as the concomitant use of two or more such antibiotics of different mechanistic classes for at least 24 hrs after the onset of hypotension or until death if the patient survived Ͻ24 hrs after hypotension documentation. The second agent had to be started within 24 hrs of the first antibiotic or within 24 hrs of the onset of hypotension (if the first agent was initiated before hypotension was documented). The combination of two ␤-lactams or a ␤-lactam and a glycopepide was not considered to represent antibiotic combination therapy (because all are cell-wall-active agents with similar mechanisms of action) for purposes of this analysis. Typical permutations of antibiotics meeting criteria for combination therapy include any two of a cell-wall-active agent (i.e., a ␤-lactam or glycopeptide), aminoglycoside, fluoroquinolone, or macrolide/clindamycin. Questionable cases or data elements were reviewed and adjudicated by the principal investigator. Cases of septic shock associated with negative or absent cultures and those caused by yeast/fungi, anaerobes, and atypical pathogens, such as Mycobacterium tuberculosis and Legionella species, were excluded ( Fig.  1 ). Patients who did not receive any appropriate antimicrobial therapy before death were also excluded.
Subsets of subject data examined in this study have been utilized for several earlier publications (5, 21, 24, 25) . Data collection methods have been described in those previous studies (5, 21) . Data were collected by trained research nurses/medical students us- ing a standardized and piloted data extraction template. Variables collected included patient demographics, baseline comorbidities, Acute Physiology and Chronic Health Evaluation II score (26) , physiologic/laboratory parameters, and the use of hemodynamic or ventilatory support. The site of infection, microbiological culture results, and the time to appropriate antimicrobial therapy from the onset of hypotension were also recorded.
Outcome Measures
The primary outcome variable was mortality over 28 days. Mortality stratified by severity of illness (Acute Physiology and Chronic Health Evaluation II score), time from initial documentation of hypotension to first appropriate antimicrobial, and time between initiation of the first and second appropriate antibiotic were identified a priori as secondary outcome measures. Other predetermined secondary end points included hospital and intensive care unit mortality and vasopressor/ inotropic support-free days in the first 30 days after shock. Exploratory analyses were performed to examine the association of any potential benefit of combination therapy according to antibiotics utilized, clinical syndrome, and primary pathogen.
Statistical Analysis
Baseline characteristics between patients receiving monotherapy and combination antibiotic therapy were compared using Student's t test or Wilcoxon's rank sum test for continuous variables, or the chi-square test for categorical variables. All reported p values were two-tailed. Because combination therapy was not randomly assigned, a propensity analysis was undertaken to account for potential confounding factors and selection biases. The propensity matching and analytic methods used in this study incorporated aspects from several reference sources (24, 27, 28) . A propensity score for combination antibiotic therapy use was developed using multivariable logistic regression. This score represents the probability that a patient would receive combination therapy based on variables that were known or suspected to influence group assignment (monotherapy or combination therapy) or to affect mortality risk. Variables included in the derivation of the propensity score are shown in Table 1 . Among these were age, gender, Acute Physiology and Chronic Health Evaluation II score, the number of day 1 organ failures, occurrence of shock before initiation or during therapy with an appropriate antibiotic, time to the initial dose of the first appropriate antibiotic (after documentation of sepsisassociated hypotension), site of infection acquisition (community, nosocomial), preexisting medical conditions, infecting organism, presence of bacteremia, primary antibiotic therapy, anatomical site of infection, volume of fluid resuscitation in the first hour of hypotension, use of therapies including source control, activated protein C, corticosteroids, mechanical ventilation, and a variety of laboratory data including white blood cell count, platelet count, the international normalized ratio, serum creatinine, and serum bicarbonate. To account for temporal and geographic practice variability, the date of intensive care unit admission and hospital sites (region/ academic vs. nonacademic) were also incorporated as matching variables.
One of the two antibiotics in each combination therapy regimen had to be designated as the primary agent in the combination for matching purposes. The required monotherapy match was prioritized as follows: ␤-lactam/vancomycin, fluoroquinolones, macrolides/clindamycin, and other. The priority-matched drug was considered the primary antibiotic and the additional drug of the combination regimen was considered the secondary/supplemental antibiotic. Aminoglycosides were always considered secondary/supplemental. Propensity scores were used to match patients who received combination therapy to a control patient receiving monotherapy using a SAS macro (SAS, Cary, NC). A greedy matching procedure selected match pairs initially identical to five decimal places of probability (29) . If no match existed at five decimal places, then matching would occur at four decimal places, and so on. If no match existed at one decimal place, then that patient receiving combination therapy was excluded from the study. To compensate for immortal time bias (30) , matching was restricted so that the minimum duration of survival (from hypotension) of the matched monotherapy case was consistently longer than the duration of time between hypotension onset and administration of the second appropriate antibiotic for the combination therapy patient (i.e., the matching monotherapy patient always lived long enough to have had the same or greater opportunity to have received a second appropriate antibiotic). This was accomplished by ensuring the monotherapy cases utilized for matching always lived at least a day (range, 1 min to 48 hrs) beyond the point that the combination therapy patient received the first dose of the second appropriate antibiotic. Using this strategy, 1223 of 1714 (71.4%) patients who received combination therapy were able to be suitably matched using propensity scores.
Mortality over 28 days was assessed using a Cox proportional hazards model. Hazard models incorporated survival data over the complete duration of the study period (28 days) or until the time of censoring (i.e., death). Mortality estimates stratified by the delay from hypotension to the first antibiotic and the delay from the first to second antibiotic (in combination regimens) were assessed by the addition of an interaction term to the hazard model (31) . A hazard or odds ratio Ͻ1 signifies decreased mortality in the combination therapy group compared to the monotherapy group. Statistical analyses were conducted using SAS version 9.1 (SAS Institute, Cary, NC). The confidence limits and p values reported reflect ␣ level of 0.05.
RESULTS

Baseline Characteristics Before Propensity Matching
Antibiotic combination therapy was administered to 1714 of 4662 (36.8%) patients with eligible bacterial septic shock (Fig. 1 ). The remaining 63.2% received monotherapy. Baseline demographics, preexisting medical conditions, and relevant clinical, physiologic, and laboratory parameters in the unmatched study population are summarized in Table 1. Males comprised 56.8% and 58.7% of the combination and monotherapy groups. The age and admission Acute Physiology and Chronic Health Evaluation II score in the unmatched study population was 61.9 (Ϯ16.2) and 23.7 (Ϯ8.0), respectively. Age was significantly younger in the combination therapy group compared with the monotherapy group; Acute Physiology and Chronic Health Evaluation II scores also trended lower. The median time to appropriate antibiotic therapy was significantly shorter in the combination therapy group, although there were no differences in fluid resuscitation volumes between groups in the first hour of hypotension.
Several epidemiologic and clinical differences between the groups existed in the unmatched cohort. The baseline prevalence of liver failure/cirrhosis, diabetes, and chronic renal failure was higher in the monotherapy group, whereas the prevalence of invasive/ metastatic malignancy, neutropenia, and other immunosuppression was higher in the combination therapy group (Table 1) . Recent elective or emergency surgery/ trauma was associated with an increased probability of receiving monotherapy. The documented presence of bacteremia, in contrast, was associated with combination therapy. The platelet count was significantly lower and the international normalized ratio trended lower in the combination therapy group. All patients required vasoactive medications because of hypotension. The need for mechanical ventilation on admission was higher in the monotherapy group. Nosocomial and healthcare-associated infections were more likely than community-acquired infections to be in the monotherapy groups. There were no statistically significant differences in the use of stress dose steroids and the provision of source control between groups, but the use of activated protein C was significantly higher with combination ther-apy. There were significant differences between groups in distribution of the anatomical site of infection, primary pathogenic organism, primary antibiotic used, and hospital sites ( Table 1) .
Baseline Characteristics After Propensity Matching
Suitable propensity matches were found for 1223 (71.4%) of 1714 patients receiving combination therapy. The c statistic for the propensity derivation model was 0.785. The range of propen-sity scores was similar in both the combination and the monotherapy groups (each, 0.01-0.96). The matching process eliminated all significant differences that existed between the combination and monotherapy groups regarding patient demographics, epidemiologic factors, preexisting medical conditions, or relevant clinical, physiologic and laboratory parameters ( Table  1) . Penicillin or carbapenem therapy of enterococci accounted for 29 of the 33 cases in which a static regimen was included in the matched cohorts. IQR, interquartile range. a Variables included in propensity derivation but not shown include the occurrence of shock while using appropriate antimicrobial therapy, appropriateness of initial antibiotic therapy, the presence of congestive heart failure, and admission serum lactate and albumin concentrations; b defined by appropriate history in context of clinical symptoms/signs of liver dysfunction per attending physicians; c medication-dependent; d creatinine 1.5ϫ normal value; e invasive or metastatic; f acquired immune deficiency syndrome, malignancy or autoimmune-related chemotherapy, Ͼ20 mg/day chronic prednisone equivalent or major organ transplant; g Staphylococcus lugdenesis, Leuconostoc, and Micrococcus species; h Serratia, Proteus, Citrobacter, Morganella, Salmonella, Providencia, and Hafnia species; i Acinetobacter, Stenotrophomonas, Aeromonas, Burkholderia, and Acaligenes; j penicillin, ampicillin, piperacillin, ticarcillin, and mezlocillin; k cloxacilin, nafcillin, and oxacillin; l piperacilln/tazobactam, ticarcilin/clavulanate, and ampicillin/sulbactam; m cefazolin; n cefuroxime, cefoxitin, and cefotetan; o cefotaxime, and ceftriaxone; p ceftazidime, cefepime, and aztreonam; q meropenem, imipenem/cilastatin, and ertapenem; r levofloxacin, ciprofloxacin, gatifloxacin, trovofloxacin, and ofloxacin; s azithromycin, erythromycin, and clarithromycin; t colistin, trimethoprim/sulfamethoxazole, linezolid, daptomycin, quinipristin/dalfopristin, and rifampin. Acute Physiology and Chronic Health Evaluation. Patients were assessed on the day of onset of shock. The range of scores for this test is 0 to 71.
Combination Antibiotic Therapy and Mortality
In the propensity-adjusted Cox model, mortality over 28 days was significantly reduced with combination therapy (444 of 1223 [36.3%] vs. 355 of 1223 [29.0%]; hazard ratio, 0.77; 95% confidence interval, 0.67-0.88; p ϭ .0002) (Fig. 2) . Stratification by Acute Physiology and Chronic Health Evaluation II score also revealed consistently reduced 28-day mortality in each assessed tertile, with significant differences in the middle and highest risk tertile groups (Table 2) .
Stratification by time from hypotension to first appropriate antimicrobial demonstrated evidence of an increased effect with greater delays (test of interaction p ϭ .39). Stratification by the delay between the first and second antimicrobial in combination therapy revealed reduced efficacy of combination therapy, with increasing delays out to 24 hrs (test for interaction p ϭ .03) ( Table 2 ). The absolute reduction in mortality in patients with the most rapid administration of the second drug (delay of 0.0 -1.0 hr) was 10.1%, with a corresponding hazard ratio of 0.68 (95% confidence interval, 0.53-0.89; p ϭ .004), whereas the absolute reduction in mortality for the most delayed second drug (maximum delay, 24 hrs) was 2.5%, with a hazard ratio of 0.89 (95% confidence interval, 0.69 -1.15; p ϭ .37) ( Table 2 ). Combination therapy reduced mortality associated with death attributable to refractory shock, sepsisrelated organ failure, and apparent nonsepsis-related causes ( Table 3 ).
In the propensity matched cohort, the proportion of ventilated patients success-fully liberated from mechanical ventilation was higher in the combination therapy group compared with the monotherapy group (67.8% vs. 61.8%; odds ratio, 1.34; 95% confidence interval, 1.12-1.61; p ϭ .001). Successful discontinuation of vasopressor/inotrope support was also higher in the combination therapy group (80.1% vs. 75.3%; odds ratio, 1.32; 95% confidence interval, 1.09-1.61; p ϭ .005). Similarly the number of ventilator and pressor/inotropefree days (in the first 30 days) was significantly greater in patients receiving combination therapy ( Table 4 ). The median hospital length of stay in survivors (total n ϭ 1647) was significantly shorter in the combination therapy group (22 days; interquartile range [IQR], 13-44; vs. 26 days; IQR, 14 -49; p ϭ .01), but the median intensive care unit length of stay was not (monotherapy: 7 days; IQR, 4 -15; vs. combination therapy: 7 days; IQR, 4 -13; p ϭ .29). Log rank analysis of the fraction of surviving patients in each group remaining on pressor/inotropic support to 28 days showed a significant (p ϭ .03) advantage for combination therapy (Fig. 3 ). An approximate 5% divergence became apparent by day 5.
Of the eight hospital/regional groupings shown in Table 1 , six demonstrated evidence of combination therapy benefit in the unadjusted analysis, with five retaining significance (p Ͻ .05) after propensity matching. The remaining three did not demonstrate a significant advantage to either combination therapy or monotherapy.
The beneficial effect of combination therapy was predominantly seen with ␤-lactams as primary therapy including both penicillins and cephalosporins ( Fig.   4 ). When ␤-lactams were included as the primary agent, combination therapy with aminoglycosides, fluoroquinolones, and macrolides/clindamycin as secondary/ supplemental agents was associated with a superior outcome compared to monotherapy with the ␤-lactam (Fig. 5) .
The benefit of combination therapy was significant for bacteremic and nonbacteremic infections (Fig. 6) . Similarly, both pneumonia and nonpneumonia infections demonstrated superiority of combination therapy (Fig. 6) . A significant benefit was also seen in both Grampositive and Gram-negative organisms and in Streptococcus pneumoniae and Enterobacteriaceae infections in particular ( Fig. 7) . For both clinical infections and specific organisms, most groups trended in favor of combination therapy.
DISCUSSION
In this retrospective, propensitymatched cohort study of septic shock, the use of combination antibiotic therapy was associated with reduced 28-day mortality. Intensive care unit and hospital mortality were similarly reduced with combination therapy. The benefit of combination therapy was greatest with shorter periods between administration of the two drugs. Mortality differences narrowed with increasing delay from the first to the second antibiotic ( Table 2) . A shorter period between documentation of hypotension and administration of the first drug was associated with improved survival but a relative reduction in the benefit of combination therapy ( Table 2) . Combination therapy was associated with more pressor-free and ventilator-free days, an increase in successful liberation of ventilatory support, and discontinuation of vasoactive medications. The benefit of combination therapy appeared to be associated primarily with combinations of ␤-lactams with aminoglycosides, fluoroquinolones, and macrolides/ clindamycin (Fig. 5) . However, the effect was consistent across most clinical infections and pathogens.
Although the use of combinations of antibiotics is relatively common in septic shock, the rationale is typically to ensure that the pathogenic organism is covered by at least one active drug in the initial regimen (as per current guidelines and recommendations) (32, 33) . An effort to ensure that the probable pathogen or pathogens are covered by more than one active agent (effective combination ther- apy) is not advised based on several metaanalyses that have failed to show a benefit of combination therapy in severe infections, including sepsis and Gram-negative bacteremia (17, 18) .
This study and a recently completed meta-regression/meta-analysis (19) suggest that combination antibiotic therapy may be advantageous in septic shock. The basis on which combination therapy provides a sur-vival benefit at higher levels of mortality risk can potentially be related to several mechanisms. These include an increased likelihood that the infecting pathogen will be susceptible to at least one of the components of the regimen; prevention of emergence of resistant superinfection (34 -36) ; potential beneficial immunomodulatory effect of the secondary agent (37, 38) ; and generation of an additive or even syn-ergistic antimicrobial effect of the combination (i.e., more rapid killing of the pathogen) (11, 15, 39 -41) .
With regard to this analysis, the possibility of increased breadth of coverage is immaterial. The study was restricted to culture-positive infections with standard sensitivity testing so that all patients were known to have been treated with one (monotherapy) or more (combina- a Excluding those where first appropriate antibiotic was administered before hypotension. tion therapy) antibiotics appropriate to their primary pathogen. Although it is difficult to rule out the possibility that increased late development of infections with resistant organisms could contribute to increased mortality in the monotherapy group, the magnitude of the effect required to produce such a large change in mortality appears improbable. Finally, immunomodulatory activity has been ascribed to macrolides (38, (42) (43) (44) (45) and, to a lesser extent, fluoroquinolones (37, 38, 46) . Data supporting direct immunomodulatory effects of aminoglycosides are very limited (47, 48) . Even so, clinically relevant immunomodulatory effects of the secondary agent would seem to be improbable as a cause of the beneficial effect because such effects would seem unlikely to exist across all groups of secondary agents (aminoglycosides, fluoroquinolones, and macrolides/clindamycin).
In addition, an immunomodulatory basis of benefit of combination therapy might also be expected to extend across all ␤-lactams rather than only the least powerful agents (in terms of standard pharmacokinetic indices, i.e., time above minimal inhibitory concentration). Given the known benefit of synergistic therapy in certain infections, including bacterial endocarditis, it would seem likely that the beneficial effect is related to faster clearance of organisms in the combination therapy patients. Antimicrobial synergy appears to be best-established for ␤-lactam/aminoglycoside combinations (49 -52) . However, similar data on synergistic activity have emerged for combinations of a ␤-lactam and fluoroquinolone (53) (54) (55) (56) (57) (58) (59) . There are also data suggesting additive effects (60) or even potential synergism (61-64) for ␤-lactam/macrolides combinations in certain circumstances. Although speculative, synergistic antimicrobial combinations may eradicate the underlying bacterial pathogens more quickly than a single drug, resulting in more rapid resolution of infection-associated physiologic instability (Fig. 3 ), leading to improved clinical cure and survival.
Interestingly, carbapenems (almost entirely imipenem/cilastatin and meropenem), extended-spectrum ␤-lactam/␤lactamase inhibitor combinations, and anti-pseudomonal cephalosporins, which tend to demonstrate optimal pharmacokinetic indices (with presumably maximal kill rates) for most septic shock pathogens, yielded the weakest evidence of benefit of combination therapy. This effect cannot be explained on the basis of immune modulation but may be explainable on the basis of a second agent's inability to substantially further increase the rate of bacterial clearance (cidality) when the most potent ␤-lactams are part of a combination regimen. . Primary antibiotic and outcome. The use of ␤-lactams as part of combination therapy was associated with reduced hazard ratio of death. A significant association with survival was seen with use of most penicillins and cephalosporins in such therapy. The benefit did not extend to antipseudomonal ␤-lactamase inhibitors, cephalosporins, and carbapenems. Combinations in which an antibiotic other than a ␤-lactam was the primary agent also did not show evidence of benefit. Monotherapy represents the reference group. MT, monotherapy; CT, combination therapy; staph, Staphylococcus; gen, generation; ceph, cephalosporin; Ps, pseudomonal; HR, unadjusted hazard ratio; CI, confidence interval. For antibiotics belonging to each group, refer to Table 1 . Data displayed as median (interquartile range).
Figure 3.
Log-rank assessment of persistence of pressor/inotrope dependence associated with combination therapy of septic shock. Combination therapy was associated with more rapid liberation from pressor/inotrope support.
As with any retrospective analysis, this study has limitations and weaknesses that merit attention. There are at least two potential time-dependent biases associated with this study. Immortal time bias is, in essence, a mathematical problem in which survival duration may be linked to an inappropriate reference point yielding an inaccurate time-dependent survival probability (30) . A retrospective study of critically ill patients with a very high early mortality risk may also demonstrate a survival duration-related selection bias. In this case, the group of patients who are known to have lived long enough to receive a second antibiotic during septic shock may be selected to more likely live to a given temporal end point than the group who cannot be known to have lived long enough to receive the second drug. Several statistical approaches can be used to control for immortal time bias. One conservative approach to control for both types of potential biases is to ensure that subjects in both groups live long enough to potentially have received the second antibiotic. For that reason, each combination therapy case was matched to a monotherapy patient who lived, at a minimum, to the equivalent time point (after initial documentation of hypotension) at which the patient receiving combination therapy was given the initial dose of the second appropriate antibiotic, i.e., the matched patient always lived long enough to have received the same or better opportunity to have been administered a second drug. In fact, because the matching of each monotherapy case patient was limited to subjects who lived at least 1 day past the point at which the combination therapy patients received the second drug (to be conservative), a consistent survival bias in favor of monotherapy is created.
Despite sophisticated methods to account for individual patient differences, retrospective studies also may be confounded by indication. Some comorbid conditions may indicate or contraindicate the addition of a second antibiotic and also could be associated with clinical outcomes. For example, aminoglycosides and, less so, fluoroquinolones may be problematic and, therefore, less frequently used in patients with acute renal failure. These patients would also be expected to have an increased mortality risk. Alternately, increased severity of illness might increase the probability of administration of a second agent generating a spurious association between combina- . Association of combination therapy with outcome stratified by clinical syndrome and characteristics. Among clinical syndromes, a significantly reduced hazard ratio for death was seen among respiratory tract infections treated with combination therapy; similar, but nonsignificant, trends were seen with septic shock attributable to other infections. In aggregate, all nonrespiratory infections also demonstrated a reduced hazard ratio with combination therapy. Similar results were found when the analysis was restricted to septic shock patients who were either bacteremic or non-bacteremic and whether or not source control was required. MT, monotherapy; CT, combination therapy; PBSI, primary bloodstream infection (no apparent anatomical source); CRI, intravascular catheter-related infection; RTI, respiratory tract infection; UTI, urinary tract infection; IAI, intraabdominal infection; CNSI, central nervous system infection; SSTI, skin and soft tissue infection; SSI, surgical site infection; ITI, intrathoracic infection (exclusive of respiratory tract); SCϩ inf, source control requiring infection; SCϪ inf, nonsource control requiring infection; bactϩ, infection associated with documented bacteremia; bactϪ, infection not associated with documented bacteremia; HR, unadjusted hazard ratio; CI, confidence interval. tion therapy and mortality. Other biases may be less obvious. We attempted to control for potential confounders through propensity matching of a variety of variables (epidemiologic factors including hospital site, laboratory measures, severity of illness, specific pathogen, clinical infection syndrome, and antibiotic used). Nonetheless, it is possible that residual confounders not recorded in the dataset could exist. Propensity methods are unable to account for these unknown factors. An obvious weakness of any retrospective design is that the allocation of patients and the use of combination therapy cannot be randomized, nor can the antibiotic regimens be standardized. Further, in this study, indications for the use of combination therapy could not be clearly defined.
This study also has important strengths. A comprehensive clinical database allowed for the identification of a large number of patients eligible for analyses in this study. Baseline differences between the combination and monotherapy groups existed, which could have the potential to bias mortality estimates; however, the large sample size allowed for a rigorously conducted propensity matched analyses whereby patients were successfully matched for Ͼ30 clinically relevant parameters. Although no retrospective method can replace the advantage of prospective randomization, propensity analyses have been demonstrated to be an effective means of reducing bias in baseline characteristics when assessing treatment effects (28, 65) . In this analysis, all significant baseline differences between study groups were adequately reconciled using this method. The inclusion of patients from multiple hospitals with a variety of clinical infections and pathogens adds further to the applicability of the findings as they relate to septic shock.
Our data strongly suggest that early empirical combination antibiotic therapy with two antibiotics of different mechanisms of action is associated with superior outcomes compared with monotherapy in the treatment of bacterial septic shock. These observational data point to the need for a large, randomized, controlled trial to examine this issue in patients with septic shock. . Association of combination therapy with outcome stratified by bacterial pathogen. In aggregate, both Gram-positive and Gram-negative pathogens yielded evidence of reduced hazard ratio for death with combination therapy. Similarly, combination therapy of enterobacteriaceae group pathogens was associated with improved survival, whereas nonenterobacteriaceae group pathogens trended in a similar direction. The only individual pathogen that yielded significant evidence of benefit of combination therapy was Streptococcus pneumoniae. GAS, group A ␤-hemolytic streptococci; nonGAS strep, ␤-hemolytic streptococci other than group A; sp, species; Ps, Pseudomonas; EB, Enterobacteriaceae; HR, unadjusted hazard ratio; CI, confidence interval. For organisms in each group, refer to Table 1 . 
APPENDIX 1
Rules to assign clinical significance to microbial isolates: 1) Clinically significant isolates from either local site and/or blood cultures were required to have been obtained within 48 hrs of onset of shock. 2) The following were considered to represent clinically significant isolates: a) Positive blood culture for any pathogen other than coagulase-negative staphylococci or other skin contaminants. b) Any growth from a normally sterile site (e.g., gall bladder, bronchial lavage, peritoneal, pleural fluid, operative tissue specimen) apart from coagulase-negative staphylococci and other skin contaminants. c) Growth of a pathogen in sputum sample of a patient with respiratory signs and symptoms or a new infiltrate on chest radiography, with no other likely source of infection. d) Growth of a pathogen in a urine sample (Ͼ10 8 organisms/L) with either local clinical symptoms or in the absence of a more plausible clinical infection site. e) Growth from a deep biopsy or a deep aspirate of a finding in soft tissue or skin. f) Concurrent, congruent, positive, semiquantitative catheter colonization (Ͼ15 colonies) with blood culture or clinical evidence of site infection. g) A positive direct measurement of Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae antigen in the sputum or cerebrospinal fluid. 3) Enterococci were considered to be clinically significant only in the absence of other more plausible pathogens. 4) Staphylococcus epidermidis was uniformly considered to be incapable of causing septic shock. Other coagulase-negative staphylococci similarly were considered to be unlikely to cause septic shock unless present as a sole isolate in multiple blood cultures in the absence of evidence of endovascular infection.
APPENDIX 2
Rules regarding antimicrobial therapy 1) The following organisms were considered sensitive to listed antibiotics (i.e., appropriate therapy) even in the absence of specific sensitivity testing: group A, B, and G streptococcus to all ␤-lactams; all Gram-positive bacteria except enterococci to vancomycin; and organisms to ␤-lactamase inhibitor combinations if sensitive to the ␤-lactam alone.
2) The following organisms were considered resistant to listed antibiotics (i.e., inappropriate therapy): Enterococci to all cephalosporins and trimethoprim/ sulfamethoxazole and Enterococcus faecalis to quinupristin-dalfopristin. 3) Clindamycin, macrolides, and thirdgeneration cephalosporins were not considered appropriate for Staphylococcus aureus septic shock irrespective of listed sensitivity. 4) Cefotaxime and ceftriaxone were not considered appropriate therapy of Pseudomonas aeruginosa irrespective of listed sensitivity. 5) Treatment with bacteriostatic antibiotics was considered appropriate therapy only in the case of sensitive enterococci treated with a penicillin or carbapenem and for any pathogen for which no commonly available bactericidal primary or supplemental agents existed. 6) Use of aminoglycosides as the supplemental/secondary antibiotic for treatment of group A streptococci (Streptococcus pyogenes) or viridans streptococci infections with an appropriate ␤-lactam or vancomycin was considered to be appropriate combination therapy even in the absence of specific sensitivity data. 7) In case of multiple isolates at a local site, appropriate therapy was considered to have been delivered if the densest pathogen was covered. If multiple pathogens were isolated at similar density, then all pathogens were required to have been covered. 8) For multiple simultaneous blood isolates, appropriate therapy had to cover all pathogens.
APPENDIX 3
